<div id="readability-page-1"><div><p><span>Sibold William John, Chief Executive Officer of Madrigal Pharmaceuticals Inc [MDGL], filed a Form 144 on December 4, 2025 with the Securities and Exchange Commission proposing to sell restricted securities:</span></p><div><table><tbody><tr><td><span>Approximate Date Of Sale</span></td><td><span>12/4/25</span></td></tr><tr><td><span>Shares</span></td><td><span>2,400</span></td></tr><tr><td><span>Broker</span></td><td><span>Morgan Stanley Smith Barney LLC</span></td></tr></tbody></table></div><p><span>Prior to the sale of restricted stock, owners must file a Form 144 with the SEC.  Upon submission of the filing to the SEC the owner is permitted to sell the shares, or any fraction thereof, within 90 days.</span></p><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

MDGL

<p>CEO Sibold William John of Madrigal Pharmaceuticals Inc filed a Form 144 with the SEC to sell 2,400 restricted shares on December 4, 2025. The sale will be managed by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing the owner to sell within 90 days of filing. The Washington Service offers insider trading analysis and data services.</p>

CEO Sibold Files To Sell 2,400 Of Madrigal Pharmaceuticals Inc [MDGL]